Lees K R, Green S T, Reid J L
University Department of Materia Medica, Stobhill General Hospital, Glasgow.
Clin Pharmacol Ther. 1988 Oct;44(4):418-25. doi: 10.1038/clpt.1988.174.
Perindopril is the ester prodrug of the angiotensin converting enzyme inhibitor S-9780. The influence of age on the pharmacokinetics and pharmacodynamics of S-9780 (1 mg administered intravenously) and perindopril (8 mg administered orally) was examined in a double-blind, crossover, acute study in eight young (29 +/- 3 years) and eight elderly (71 +/- 3 years) healthy subjects. Mild headache and light-headedness were the only adverse effects and were more common in the younger subjects. Blood pressure fall was greater in the elderly even after correction for starting blood pressure. Bioavailability of S-9780 was increased in the elderly (35% +/- 17% compared with 19% +/- 7%; p less than 0.025) mainly because of increased conversion rather than absorption. Renal clearance of S-9780 was lower in the elderly (67 +/- 31 ml/min compared with 110 +/- 39 ml/min; p less than 0.03). Dose reduction of approximately 50% is suggested for elderly patients with further adjustment proportional to any preexisting diminished renal function.
培哚普利是血管紧张素转换酶抑制剂S-9780的酯前体药物。在一项针对8名年轻(29±3岁)和8名老年(71±3岁)健康受试者的双盲、交叉、急性研究中,研究了年龄对静脉注射1 mg S-9780和口服8 mg培哚普利的药代动力学和药效学的影响。轻度头痛和头晕是仅有的不良反应,且在年轻受试者中更常见。即使校正起始血压后,老年人的血压下降幅度仍更大。老年人中S-9780的生物利用度有所增加(35%±17%,而年轻人为19%±7%;p<0.025),主要是因为转化率增加而非吸收增加。老年人中S-9780的肾清除率较低(67±31 ml/min,而年轻人为110±39 ml/min;p<0.03)。建议老年患者剂量减少约50%,并根据任何已存在的肾功能减退情况进一步按比例调整。